Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

2014 San Antonio Breast Cancer Symposium

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

Lee S. Schwartzberg, MD, FACP, and Ian E. Krop, MD, PhD, on PI3K and PD-L1 Inhibition Data

Lee S. Schwartzberg, MD, FACP of The West Clinic and Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute discuss the FERGI trial and data from phase I and phase II studies.

Breast Cancer

Prudence Francis, MD, and Hope Rugo, MD

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

Prudence Francis, MD, of Peter MacCallum Cancer Centre, and Hope Rugo, MD, of the University of California, San Francisco, discuss data from abstract S3-08, "Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial."

Breast Cancer

Matthew J. Ellis, MD

Matthew J. Ellis, MD, on Endocrine Therapy–Resistant Breast Cancer

Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine, offers a brief synopsis of his plenary lecture, "Genome-Directed Therapeutics for Endocrine Therapy–Resistant Estrogen Receptor–Positive Breast Cancer."

Breast Cancer

Jame Abraham, MD, FACP

Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer

Jame Abraham, MD, FACP, of the Cleveland Clinic, offers his thoughts on abstract S1-09, "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.

Breast Cancer

Ann H. Partridge, MD, MPH

Ann H. Partridge, MD, MPH, on Patient-Reported Outcomes From the SOFT Trial

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, on abstract S3-09, “Patient-reported endocrine symptoms, sexual functioning and quality of life in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen alone vs tamoxifen plus ovarian function suppression in premenopausal women with hormone receptor–positive early breast cancer.”

May

Today In Oncology

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

Related Videos

Lee S. Schwartzberg, MD, FACP, and Ian E. Krop, MD, PhD, on PI3K and PD-L1 Inhibition Data

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

Matthew J. Ellis, MD, on Endocrine Therapy–Resistant Breast Cancer

Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer

Ann H. Partridge, MD, MPH, on Patient-Reported Outcomes From the SOFT Trial

Ablative Radiation Therapy for Resectable Pancreatic Ductal Adenocarcinoma

Patterns in Oncology Drug Use After Accelerated Approval Is Withdrawn

Collaborative Strategy Involving AI Human Task Sharing Could Help Minimize Mammogram Costs

FDA Approves Doublet for KRAS-Mutated, Recurrent, Low-Grade Serous Ovarian Cancer

Breast Cancer Radiotherapy 1- vs 3-Week Course